FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891007000> ?p ?o ?g. }

• W2891007000 endingPage "5605" @default.
• W2891007000 startingPage "5601" @default.
• W2891007000 abstract "Immuno-checkpoint inhibitors (ICI) have become an effective treatment option for non-small-cell lung cancer patients. However, ICI therapy was reported to be less effective in patients with epidermal growth factor receptor (EGFR) mutations than in those with wild-type EGFR. We report here that an non-small-cell lung cancer patient with the EGFR mutant T790M showed a programmed cell death ligand 1 (PD-L1) expression level that increased from <25% to >90% after eighth-line osimertinib therapy. He was treated with pembrolizumab as a ninth-line treatment, and attained stable disease. After the pembrolizumab therapy, he was treated with gemcitabine, which produced a good response despite being the 10th-line treatment. We should consider administering ICI and chemotherapy even to EGFR mutant patients after failure of EGFR tyrosine kinase inhibitor, especially in cases with high PD-LI expression." @default.
• W2891007000 created "2018-09-27" @default.
• W2891007000 creator A5003800040 @default.
• W2891007000 creator A5011282366 @default.
• W2891007000 creator A5011533142 @default.
• W2891007000 creator A5013701729 @default.
• W2891007000 creator A5019949204 @default.
• W2891007000 creator A5023733871 @default.
• W2891007000 creator A5027322897 @default.
• W2891007000 creator A5034162457 @default.
• W2891007000 creator A5036380788 @default.
• W2891007000 creator A5048704135 @default.
• W2891007000 creator A5054938771 @default.
• W2891007000 creator A5069386130 @default.
• W2891007000 creator A5074566020 @default.
• W2891007000 creator A5079429350 @default.
• W2891007000 creator A5084969110 @default.
• W2891007000 creator A5087511299 @default.
• W2891007000 creator A5087922163 @default.
• W2891007000 date "2018-09-01" @default.
• W2891007000 modified "2023-09-22" @default.
• W2891007000 title "Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression" @default.
• W2891007000 cites W1911047310 @default.
• W2891007000 cites W1980980429 @default.
• W2891007000 cites W2004630197 @default.
• W2891007000 cites W2022873825 @default.
• W2891007000 cites W2049553585 @default.
• W2891007000 cites W2066671159 @default.
• W2891007000 cites W2104347254 @default.
• W2891007000 cites W2143178874 @default.
• W2891007000 cites W2147592245 @default.
• W2891007000 cites W2149219947 @default.
• W2891007000 cites W2156353875 @default.
• W2891007000 cites W2177804157 @default.
• W2891007000 cites W2184779060 @default.
• W2891007000 cites W2198093519 @default.
• W2891007000 cites W2400514548 @default.
• W2891007000 cites W2513437066 @default.
• W2891007000 cites W2538232731 @default.
• W2891007000 cites W2560367415 @default.
• W2891007000 cites W2560717039 @default.
• W2891007000 cites W2572174216 @default.
• W2891007000 cites W2606022415 @default.
• W2891007000 cites W2622595542 @default.
• W2891007000 cites W2626831245 @default.
• W2891007000 cites W2635951006 @default.
• W2891007000 cites W2743577629 @default.
• W2891007000 cites W2744409114 @default.
• W2891007000 cites W2753341704 @default.
• W2891007000 cites W2765962239 @default.
• W2891007000 cites W2784920809 @default.
• W2891007000 doi "https://doi.org/10.2147/ott.s168598" @default.
• W2891007000 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6135433" @default.
• W2891007000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30237726" @default.
• W2891007000 hasPublicationYear "2018" @default.
• W2891007000 type Work @default.
• W2891007000 sameAs 2891007000 @default.
• W2891007000 citedByCount "4" @default.
• W2891007000 countsByYear W28910070002019 @default.
• W2891007000 countsByYear W28910070002020 @default.
• W2891007000 countsByYear W28910070002021 @default.
• W2891007000 countsByYear W28910070002022 @default.
• W2891007000 crossrefType "journal-article" @default.
• W2891007000 hasAuthorship W2891007000A5003800040 @default.
• W2891007000 hasAuthorship W2891007000A5011282366 @default.
• W2891007000 hasAuthorship W2891007000A5011533142 @default.
• W2891007000 hasAuthorship W2891007000A5013701729 @default.
• W2891007000 hasAuthorship W2891007000A5019949204 @default.
• W2891007000 hasAuthorship W2891007000A5023733871 @default.
• W2891007000 hasAuthorship W2891007000A5027322897 @default.
• W2891007000 hasAuthorship W2891007000A5034162457 @default.
• W2891007000 hasAuthorship W2891007000A5036380788 @default.
• W2891007000 hasAuthorship W2891007000A5048704135 @default.
• W2891007000 hasAuthorship W2891007000A5054938771 @default.
• W2891007000 hasAuthorship W2891007000A5069386130 @default.
• W2891007000 hasAuthorship W2891007000A5074566020 @default.
• W2891007000 hasAuthorship W2891007000A5079429350 @default.
• W2891007000 hasAuthorship W2891007000A5084969110 @default.
• W2891007000 hasAuthorship W2891007000A5087511299 @default.
• W2891007000 hasAuthorship W2891007000A5087922163 @default.
• W2891007000 hasBestOaLocation W28910070001 @default.
• W2891007000 hasConcept C121608353 @default.
• W2891007000 hasConcept C126322002 @default.
• W2891007000 hasConcept C143998085 @default.
• W2891007000 hasConcept C170493617 @default.
• W2891007000 hasConcept C2776256026 @default.
• W2891007000 hasConcept C2776694085 @default.
• W2891007000 hasConcept C2777626846 @default.
• W2891007000 hasConcept C2777701055 @default.
• W2891007000 hasConcept C2777930144 @default.
• W2891007000 hasConcept C2778087573 @default.
• W2891007000 hasConcept C2779438470 @default.
• W2891007000 hasConcept C2780057760 @default.
• W2891007000 hasConcept C2780258809 @default.
• W2891007000 hasConcept C2780580887 @default.
• W2891007000 hasConcept C2781053074 @default.
• W2891007000 hasConcept C42362537 @default.
• W2891007000 hasConcept C502942594 @default.

• next